AbCellera Biologics Inc. (ABCL) Institutional Ownership

Ownership Summary

AbCellera Biologics Inc. (NASDAQ:ABCL) is held by 144 institutional investors per 13F filings through December 2025.

• Collectively, these holders controlled 36.3% of AbCellera Biologics's outstanding shares in December 2025, up from 35.9% in September 2025.
• Their total shares held in ABCL increased 17.72% from the prior quarter, while the number of investors in AbCellera Biologics increased 1.41% year over year.
• Activity in ABCL broke down as 80 buyers, 38 sellers, and 26 unchanged among 144 total holders.
• In total, institutional investors held 108.59Mn shares in AbCellera Biologics as of December 2025, up by 16.35Mn shares quarter on quarter, and down 17.01Mn shares year over year.
• BAKER BROS. ADVISORS LP leads ownership in ABCL with 27.53Mn shares as of December 31, 2025, equal to 9.21% of outstanding shares.
• Top purchasers of ABCL stock for the quarter ending December 2025 included UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (7.88Mn), Goldman Sachs Group Inc (4.09Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (2.05Mn), JANE STREET GROUP, LLC (999.94K), Point72 Asset Management, L.P. (976.51K).
• Top sellers of ABCL stock for the quarter ending December 2025 included Bank Of America Corp /De/ (2.2Mn), RENAISSANCE TECHNOLOGIES LLC (971.5K), MILLENNIUM MANAGEMENT LLC (656.2K), Jump Financial, LLC (594.33K), UBS Group AG (549.79K).
• AbCellera Biologics's 10 largest shareholders as of December 2025 include BAKER BROS. ADVISORS LP (27.53Mn), Capital World Investors (13.36Mn), UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (7.88Mn), TWO SIGMA INVESTMENTS, LP (5.81Mn), TWO SIGMA ADVISERS, LP (4.88Mn), Goldman Sachs Group Inc (4.34Mn), ArrowMark Colorado Holdings LLC (4.11Mn), BlackRock, Inc. (3.87Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (3.77Mn), Morgan Stanley (3.0Mn) per Business Quant data.